Baseline Characteristics

Pre NLR < 3 (N = 19)Pre NLR ≥ 3 (N = 23)All (N = 42)p-value
Median, Age – median (range)61 (45-85)61 (24-82)61 (24-85)0.859
 Race– no. (%)0.339
 Caucasian14 (74)16 (70)30 (71)
 African-American5 (26)4 (17)9 (21)
 Asian0 (0)3 (13)3 (7)
 Histology– no. (%)0.330
 Clear Cell17 (89)16 (70)33 (79)
 Non-Clear cell2 (11)9 (30)9 (21)
Smoking Status– no. (%)>0.99
 No10 (53)11 (48)21 (50)
 Yes9 (47)12 (52)21 (50)
Number of Prior anti-VEGF Therapies– no. (%)0.093
 ≤116 (84)13 (57)29 (69)
 > 13 (16)10 (43)13 (31)
Duration of prior anti-VEGF Therapies– no. (%)>0.99
 < 6 Months8 (42)10 (43)18 (43)
 ≥ 6 Months11 (58)13 (57)24 (57)
NLR at Day 15– no. (%)<0.001
 < 315 (79)2 (9)17 (40)
 ≥ 34 (21)20 (87)24 (57)
NLR at Cycle 3– no. (%)a0.001
 < 313 (68)3 (13)16 (38)
 ≥ 34 (21)16 (70)20 (48)
Types of anti-VEGF Therapies – no. (%)
 Pazopanib10 (34)10 (77)20 (48)0.019
 Sunitinib6 (21)9 (69)15 (36)0.005
 Axitinib0 (0)9 (69)9 (21)<0.001
 Sorafenib0 (0)6 (46)6 (14)<0.001
 Bevacizumab2 (7)5 (38)7 (17)0.021
 Everolimus2 (7)5 (38)7 (17)0.021
 IL210 (34)10 (77)20 (48)0.019
Histology – no. (%)0.330
 Clear17 (89)16 (70)33 (79)
 Clear Cell W/ Sarcamatoid Features0 (0)3 (13)3 (7)
 Clear Cell W/ Papillary Features2 (1)3 (13)5 (12)
 Medullary0 (0)1 (4)1 (2)
Heng Prognostic Score– no. (%)0.509
 Low4 (21)8 (35)12 (29)
 Intermediate10 (53)12 (52)22 (52)
 High5 (26)3 (13)8 (19)
MSKCC Prognostic Score– no. (%)0.317
 Low4 (21)9 (39)13 (31)
 Intermediate15 (79)14 (61)29 (69)
Type of Immune Checkpoint Inhibitor Therapy– no. (%)0.220
 Nivolumab19 (66)10 (77)29 (69)
 Nivolumab plus Nexavar0 (0)1 (8)1 (2)
 Nivolumab plus Votrient1 (3)2 (15)3 (7)
 Nivolumab + Ipilimumab1 (3)0 (0)1 (2)
 Ipilimumab0 (0)0 (0)0 (0)
 Avelumab1 (3)0 (0)1 (2)
 Pembrolizumab and Axitinib5 (17)0 (0)5 (12)
 Atezolizumab and Avastin2 (7)0 (0)2 (5)

aData are not available for 6 patients